相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms
Masakazu Koshibu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2019)
Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure
T. Kimura et al.
DIABETES & METABOLISM (2018)
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Ben Jones et al.
NATURE COMMUNICATIONS (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial
Bernt Johan von Scholten et al.
DIABETES OBESITY & METABOLISM (2017)
Sustained expression of GLP-1 receptor differentially modulates β-cell functions in diabetic and nondiabetic mice
Fumiyo Kubo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Line S. Bisgaard et al.
PLOS ONE (2016)
Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function (vol 18, pg 2388, 2009)
Luan Shu et al.
HUMAN MOLECULAR GENETICS (2015)
GLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase A
Yao Dai et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis
Yuko Tashiro et al.
PEPTIDES (2014)
The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective
Manfredi Rizzo et al.
CLINICAL LIPIDOLOGY (2013)
The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model
Tracey Gaspari et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain
Vadivel Parthsarathy et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Effect of alogliptin, pioglitazone and glargine on pancreatic β-cells in diabetic db/db mice
Satoshi Kawashima et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
Tracey Gaspari et al.
DIABETES & VASCULAR DISEASE RESEARCH (2011)
Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
Masayuki Arakawa et al.
DIABETES (2010)
被撤回的出版物: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells (Retracted article. See vol. 55, pg. 533, 2012)
Y. Hattori et al.
DIABETOLOGIA (2010)
Downregulation of GLP-1 and GIP receptor expression by hyperglycemia - Possible contribution to impaired incretin effects in diabetes
Gang Xu et al.
DIABETES (2007)
分享论文
